Close Menu

hereditary cancer

Those involved in the project hope to demonstrate that a screening program that provides BRCA testing to women starting age 30 can be cost-effective and a public health benefit.

Geisinger is hoping to help others around the country implement precision medicine, which requires significant investment in genomics expertise, as well as infrastructural and operational changes.

For the three months ended Sept. 30, the firm reported total revenues of $190.2 million, compared to $177.5 million in Q1 2017, beating the consensus Wall Street estimate.

Rainbow Genomics will offer exome-sequencing based screening and diagnostic tests developed by Baylor Genetics to patients in Asia.

Despite years of experience of returning genetic test results, clinicians and researchers are still faced with many questions, such as what to do about VUS and secondary findings.

Researchers from MSKCC reported today in JAMA that of 1,040 cancer patients referred for germline mutation testing, 18 percent had actionable variants.

The company estimates that the quality control issue resulted in between two and 15 patients getting a false negative result. 

The company plans to use proceeds to further invest in its development of molecular testing and other strategies in the preventive medicine space.

Through prospective pancreatic ductal adenocarcinoma testing, researchers saw germline mutations in new genes and in cases outside of current germline testing criteria.

A curation working group established a framework that considers the nature and strength of the available evidence when evaluating gene-disease associations.

Pages

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.